Evidence map›Paper›PMID 42244080›Full record

ArticleCancer medicine2026

Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population-Based Study in Japan.

Haruka Kudo, Kayo Nakata, Kenji Kishimoto, Toshiki Ikawa, Yoko Iwaki, Yoshihiro Kuwabara, Toshitaka Morishima, Isao Miyashiro

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haruka KudoCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Kayo NakataCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Kenji KishimotoCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Toshiki IkawaCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Yoko IwakiCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Yoshihiro KuwabaraCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Toshitaka MorishimaCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID https://orcid.org/0000-0002-0747-3287
Isao MiyashiroCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Funding

Japan Society for the Promotion of Science 25K24177Ministry of Health, Labour and Welfare JPMH23EA1033
6 · The paper itself

Abstract

Owing to improved prognosis, cancer survivors are a growing population; however, little is known about their prevalence in Asian countries. This study estimated the prevalence and characteristics of cancer survivors in Japan, including long-term survivors. Using data from the Osaka Cancer Registry, which covers 8.8 million residents in Osaka Prefecture, Japan, we identified individuals diagnosed with cancer between 1975 and 2019 who were alive in 2019. Cancer prevalence was calculated as the number of patients alive in 2019, stratified by sex, age in 2019, time since diagnosis, and 22 cancer types. National estimates were obtained by applying sex- and age-specific prevalence proportions in Osaka to the Japanese population. In 2019, 461,489 cancer survivors were living in Osaka Prefecture (5.4% of the prefectural population; 5221 per 100,000). Most were older adults, with 83% of males (n = 188,881) and 70% of females (n = 163,331) aged ≥ 65 years in 2019. Long-term survivors (≥ 10 years after diagnosis) comprised 34% of all survivors. These patterns varied across cancer types. Nationally, an estimated 6.9 million individuals (5.5% of the national population) lived after a cancer diagnosis. Based on 44 years of follow-up data, our findings highlighted a substantial subgroup of cancer survivors requiring long-term treatment, follow-up care, and age-specific support. These findings may provide useful insights for healthcare planning and cancer survivor policies in aging societies.

Indexed as

Cancer SurvivorsNeoplasmsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansInfantInfant, NewbornJapanMaleMiddle AgedPrevalencecancer registrycancer survivorspopulation‐based studyprevalence

Identifiers

PMID42244080
PMCPMC13238676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.